

ASX ANNOUNCEMENT

8 November 2022

JHC's Clinical Trial peer-reviewed and published in Nature Portfolio

- Results from the second clinical study by Joondalup Health Campus (JHC) have been published in Nature magazine's digital health platform - Nature Portfolio Journals (NPJ)
- JHC's second Clinical Study validated the accuracy, interpretability, usability, and acceptability of the HeraBEAT smart foetal heart rate monitor in prolonged monitoring sessions such as Non-Stress Tests (NSTs) or Cardiotocography (CTGs), when compared to the industry gold standard hospital-based equipment

HeraMED Limited (ASX:HMD) ("HeraMED" or the "Company"), a medical data and technology company leading the digital transformation of maternity care, is pleased to announce the publication of the second Clinical Trial by Joondalup Health Campus in Nature Portfolio, part of Nature.com. The Clinical Trial results were published on ASX on 2 May 2022.

This publication represents a significant milestone for HeraMED for several reasons; the validation of the results that found the technology to be comparable to the current standard of care hospital-based CTG machines, the conclusion that the device can be used for remote and home monitoring and that this has not been possible before.

A link to the full publication can be found on the Company's website <https://hera-med.com/investor-relations/>

-ENDS-

This announcement has been authorised by the Board of HeraMED Limited.

HeraMED Limited

CEO and Co-Founder
David Groberman
M: +972 52 6991188
E: David@hera-med.com

Company Secretary

Jonathan Hart
T: +61 2 8379 2961
E: Jonathan@hera-med.com

Investor Relations

Tim Chapman
T: +61 419 897 062
E: info@hera-med.com

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence and big data

About HeraCARE:

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.

About Joondalup Health Campus:

Joondalup Health Campus (JHC) is a general hospital in Perth's northern suburbs that offers a comprehensive range of medical and surgical services including emergency, intensive care, maternity, neonatal and paediatric services, aged care and rehabilitation and mental health. JHC is managed by Australia's largest private hospital operator, Ramsay Health Care, and has a long-standing public-private partnership agreement with the WA State Government.